What is VOCABRIA + REKAMBYS?
The first and only, complete long acting injectable regimen for HIV-1
VOCABRIA injection is indicated, in combination with REKAMBYS injection, for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.1
VOCABRIA + REKAMBYS is a different way to dose HIV-1 treatment.1,2 The treatment regimen comprises VOCABRIA (cabotegravir), a second-generation INI, and REKAMBYS (rilpivirine), an NNRTI. Both are formulated as extended-release suspensions that enable every 2-month dosing.1,2
Once a patient’s long-acting regimen is established, they will receive just 6 treatments a year.1 VOCABRIA + REKAMBYS can offer some people living with HIV freedom from taking regular daily oral medication and the challenges associated with it.1,3
Learn more from a colleague and a patient
HIV-1=human immunodeficiency virus type 1; INI=integrase inhibitor; NNRTI=non-nucleoside reverse transcriptase inhibitor.
- VOCABRIA Summary of Product Characteristics. ViiV Healthcare.
- REKAMBYS Summary of Product Characteristics. Janssen Healthcare.
- de Los Rios P, Okoli C, Castellanos E, et al. Physical, emotional, and psychosocial challenges associated with daily dosing of HIV medications and their impact on indicators of quality of life: findings from the Positive Perspectives Study. AIDS Behav. Published online ahead of print: October 7, 2020. doi: 10.1007/s10461-020-03055-1.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
REKAMBYS (rilpivirine long acting injection), including the trademark is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.
PM-GB-CBR-WCNT-210001v3 I April 2022
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.